Generate Biomedicines has formally filed to go public in the United States, indicating plans to offer 25 million shares at a proposed price range of $15 to $17 per share. If the issuance is priced at the top of that range and all shares are sold as planned, the company could raise as much as $425 million.
The biotechnology firm intends to list its shares on the Nasdaq exchange under the ticker symbol GENB. The filing names a syndicate of underwriters that will manage the deal: Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities and Cantor.
Generate Biomedicines, founded in 2018 and headquartered in Cambridge, Massachusetts, identifies its primary activity as using machine learning methods to design and optimize proteins for therapeutic use. The company's stated therapeutic focus areas include immunology, oncology and infectious diseases.
The prospectus outlines the planned share count and price band but does not guarantee the final number of shares sold or the definitive per-share price. The headline figure of up to $425 million represents the maximum gross proceeds based on the proposed share count multiplied by the high end of the indicated price range.
The filing lists the established investment banks that will serve as underwriters for the offering and notes the intended Nasdaq listing under the ticker GENB. Beyond the core details of share quantity, price range, underwriter roster, corporate focus and Nasdaq intention, the filing provides no additional operational or financial disclosures in this brief announcement.
Summary
- Generate Biomedicines has filed for a U.S. initial public offering aiming to sell 25 million shares at $15 to $17 per share, potentially raising up to $425 million.
- The company, founded in 2018 and based in Cambridge, Massachusetts, applies machine learning to protein design for therapeutic purposes with a focus on immunology, oncology and infectious diseases.
- Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities and Cantor are listed as underwriters; the intended Nasdaq ticker is GENB.